Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169+ macrophages by metastatic breast cancers
Authors:
Open Access
- 23 August 2024
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 107, 105271
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppressionMolecular Oncology, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasisCell Reports, 2021
- Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor GrowthCell Reports, 2020
- Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune LandscapeImmunity, 2018
- Reduced number of CD169+ macrophages in pre‐metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patientsThe Prostate, 2017
- Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor ImmunityCell Metabolism, 2016
- The lymph node pre-metastatic nicheJournal of Molecular Medicine, 2015
- CD169+ macrophages at the crossroads of antigen presentationTrends in Immunology, 2012
- CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated AntigensImmunity, 2011